Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Shenker

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Receptors & Channels|November 1, 2002
Activating mutations of the lutropin choriogonadotropin receptor in precocious pubertyAndrew Shenker
Thrombosis and Haemostasis|October 28, 2010
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assayYu Chen Barrett, Zhaoqing Wang, Charles Frost, et al.
Clinical Pharmacology in Drug Development|August 3, 2021
Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral AdministrationCharles Frost, Samira Garonzik, Andrew Shenker, et al.
Journal of Clinical Pharmacology|March 27, 2018
Regional Gastrointestinal Absorption of Apixaban in Healthy SubjectsWonkyung Byon, Sunil Nepal, Alan E Schuster, et al.
International Journal of Neonatal Screening|November 24, 2025
Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature ReviewLucia Laugwitz, Andrew Shenker, Erica F Sluys, et al.
Clinical Pharmacology : Advances and Applications|December 1, 2018
Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjectsCharles Frost, Andrew Shenker, Stanford Jhee, et al.
Clinical Pharmacokinetics|January 10, 2015
Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixabanCharles E Frost, Yan Song, Andrew Shenker, et al.
Endocrine Research|January 26, 2006
A novel double mutation in the luteinizing hormone receptor in a kindred with familial Leydig cell hypoplasia and male pseudohermaphroditismRobin Pals-Rylaarsdam, Guoquan Liu, Wendy Brickman, et al.
Journal of Clinical Pharmacology|September 12, 2015
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixabanMing Chang, Zhigang Yu, Andrew Shenker, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 11, 2016
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor XaBlisse Vakkalagadda, Charles Frost, Wonkyung Byon, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Receptors & Channels|November 1, 2002
Activating mutations of the lutropin choriogonadotropin receptor in precocious pubertyAndrew Shenker
Thrombosis and Haemostasis|October 28, 2010
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assayYu Chen Barrett, Zhaoqing Wang, Charles Frost, et al.
Clinical Pharmacology in Drug Development|August 3, 2021
Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral AdministrationCharles Frost, Samira Garonzik, Andrew Shenker, et al.
Journal of Clinical Pharmacology|March 27, 2018
Regional Gastrointestinal Absorption of Apixaban in Healthy SubjectsWonkyung Byon, Sunil Nepal, Alan E Schuster, et al.
International Journal of Neonatal Screening|November 24, 2025
Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature ReviewLucia Laugwitz, Andrew Shenker, Erica F Sluys, et al.
Clinical Pharmacology : Advances and Applications|December 1, 2018
Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjectsCharles Frost, Andrew Shenker, Stanford Jhee, et al.
Clinical Pharmacokinetics|January 10, 2015
Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixabanCharles E Frost, Yan Song, Andrew Shenker, et al.
Endocrine Research|January 26, 2006
A novel double mutation in the luteinizing hormone receptor in a kindred with familial Leydig cell hypoplasia and male pseudohermaphroditismRobin Pals-Rylaarsdam, Guoquan Liu, Wendy Brickman, et al.
Journal of Clinical Pharmacology|September 12, 2015
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixabanMing Chang, Zhigang Yu, Andrew Shenker, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 11, 2016
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor XaBlisse Vakkalagadda, Charles Frost, Wonkyung Byon, et al.
Pageof 2